Search Site
Home >> Signaling Pathways >> Apoptosis >> TNF-α >> Pomalidomide (CC-4047)
Related Biochemicals Related Antibodies

Pomalidomide (CC-4047)

Antitumor compound, inhibits angiogenesis

Pomalidomide (CC-4047)

Catalog No. A4212
Size Price Stock Qty
Evaluation Sample $28.00 In stock
5mg $45.00 In stock
10mg $75.00 In stock
50mg $230.00 In stock
200mg $650.00 In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

Pomalidomide (CC-4047)

Related Biological Data

Pomalidomide (CC-4047)

Related Biological Data

Pomalidomide (CC-4047)

Biological Activity

Description Pomalidomide is an inhibitor of LPS-induced TNF-α release with IC50 of 13 nM.
Targets TNF-α          
IC50 13 nM          

Pomalidomide (CC-4047) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Pomalidomide (CC-4047) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 19171-19-8 SDF Download SDF
Synonyms Actimid,4-Aminothalidomide,CC 4047
Chemical Name 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
Canonical SMILES C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N
Formula C13H11N3O4 M.Wt 273.2
Solubility Soluble in DMSO Storage Store at -20°C
Shipping Condition: Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

View Related Products By Research Topics

Background

Pomalidomide, previously known as CC-4047 or actimid, is a potent immunomodulatory molecule that exhibits antineoplastic activity for the treatment of hematological malignancies, especially relapsed and refractory multiple myeloma (MM). As a derivative of thalidomide, pomalidomide has a similar chemical structure as thalidomide except for the addition of two oxo groups in the phthaloyl ring and an amino group at the fourth position. Generally, as an immunomodulatory molecule, pomalidomide demonstrates antitumor activity through a mechanism of blocking the tumor microenvironment by modulation of tumor-supporting cytokines (TNF-α, IL-6, IL-8 and VEGF), directly down-regulating key functions of tumor cells, and engaging support from non-immune host cells.

Reference

AA Chanan-Khan, A Swaika, A Paulus, SK Kumar, JR Mikhael, SV Rajkumar, A Dispenzieri, and MQ Lacy. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer Journal (2013) 3, el43

Evangelos Terpos, Nikolaos Kanellias, Dimitrios Christoulas, Efstathios Kastritis, and Meletios A Dimopoulos. Pomalidomide: a novel drug to treat relapsed and refractory multiple myeloma. Onco Targets Ther 2013; 6: 531-538